One limitation of ASCT is the potential reinfusion of tumor cells contaminating PBSC. The Eligix B cell SC system consists of high-density microparticles coated with anti-B cell antibodies. To determine if this system eliminates B cells and lymphoma cells from PBSC, immunocytochemistry and PCR of the bcl-2/IgH rearrangement were performed, and correlated with patient outcome after ASCT. Eligible patients (n ¼ 29) had relapsed or transformed follicular NHL with bone marrow involvement o20%, and all lymph nodes o5 cm. PBSCs were mobilized with cyclophosphamide/G-CSF (n ¼ 21), and patients were conditioned with cyclophosphamide, carmustine and etoposide.Using immunocytochemistry on PBSC, the median number of CD20+ cells pre-purge was 310/10 6 (range 0-16692) and post-purge was 0.75/10 6
Follicular lymphoma, a tumor thought to arise from germinal center B cells, is the most common type of indolent non-Hodgkin's lymphoma (NHL) and is not curable with standard therapies.
1,2 A total of 85% of patients with follicular lymphoma have t(14; 18), which juxtaposes the bcl-2 proto-oncogene to the Ig heavychain region. 3 Enhanced transcription from this translocation results in a constituently high level of bcl-2 protein, which is involved in the control of apoptosis and appears to play a central role in the pathogenesis of follicular lymphoma. 4 Detection of this translocation using the polymerase chain reaction (PCR) represents a sensitive molecular marker to detect the presence of follicular lymphoma. 5 Patients who achieve 'molecular response' (PCR negativity for bcl-2) after certain treatments for follicular lymphoma appear to have prolonged disease-free survival (DFS), although this is controversial and the subject of ongoing research. [6] [7] [8] High-dose chemotherapy or chemoradiotherapy followed by autologous stem cell transplantation (ASCT) results in prolonged DFS in a substantial subset of patients with follicular NHL that has progressed after chemotherapy. [9] [10] [11] [12] When bone marrow is used as a source of stem cells for ASCT, the detection of lymphoma cells by PCR is a highly significant predictor of subsequent relapse. 13 Moreover, following ex vivo purging of autologous marrow, the absence of residual lymphoma cells detected by PCR in reinfused marrow is strongly associated with continuous clinical remission after ASCT. 14 The majority of ex vivo purging trials have utilized bone marrow as the source of stem cells, and an expensive, timeconsuming method of B cell depletion with combinations of murine monoclonal antibodies and rabbit complement. 15 The Eligix B cell SC system is a novel purging device coated with anti-B cell monoclonal antibodies, which can rapidly deplete B cells from peripheral blood stem cells (PBSC). In a pilot study to assess the safety of purging PBSC using this device in patients with relapsed B cell NHL, this process did not negatively impact on engraftment after ASCT, and purging with the Eligix B cell SC system reduced the number of B cells to undetectable levels for seven of eight patients with detectable B cells prior to depletion. 16 Given this safety profile, we conducted a study to determine if the Eligix B cell SC system eliminated tumor cells from apheresis products as measured by immunohistochemistry and quantitative PCR for the t(14;18), and correlated these results to clinical outcome after ASCT in patients with follicular NHL. The device effectively depleted products of B cells; however, the low rate of PCR positive products precluded evaluation of tumor cell purging efficiency. This low rate of PCR-positive PBSC was not predictive of subsequent prolonged DFS after ASCT.
Patients and methods
This protocol was approved by the Human Protection Committee at Dana-Farber/Partners Cancer Care, and written informed consent was obtained prior to enrollment in all cases.
Patients
Eligible patients were between 18 and 70 years of age, and had histologically -confirmed follicular NHL grades 1-3 using the World Health Organization lymphoma classification 17 or transformed follicular lymphoma as previously defined. 18 Immunophenotypic studies of NHL cells or tissue documenting CD19 or CD20 presence was required. Patients had to be in second or further remission with a minimal disease state, as defined by bone marrow involvement o20% of the intratrabecular space and tumor masses o5 cm in each dimension. Also, eligible were those patients who failed to achieve remission with primary induction therapy or patients with transformed NHL who achieved a minimal disease state with chemotherapy or radiotherapy. Masses larger than 5 cm were allowed if previously irradiated as described, 19 or if negative on imaging with gallium SPECT or FDG positron emission tomographic scanning. Patients were excluded if they had an uncontrolled bacterial, viral or fungal infection, concomitant active, symptomatic malignancy, impaired cardiac function or impaired pulmonary function. Patients were also excluded if they were treated with unconjugated or conjugated anti-B cell monoclonal antibody (eg, rituximab, Campath I-H or ibritumomab tiuxetan) within 3 months prior to enrollment, or had known hypersensitivity to nickel or to mouse proteins.
Treatment
For mobilization therapy, patients received cyclophosphamide, 3 gm/m 2 followed by G-CSF, 10 mg/kg subcutaneously each day beginning 24 h after cyclophosphamide until pheresis was complete. Peripheral blood stem cells were collected once the peripheral blood CD34+-cell count was 15 cells/ml. The collection goal was to process three blood volumes per day until a minimum of 2.0 Â 10 6 CD34+ cells/kg was reached after processing. If o2.0 Â 10 6 CD34+ cells/kg were cryopreserved after stem cell collections, or if the patient did not reach the goal of 15 CD34+ cells/ml, the patient was removed from the study. 20 G-CSF 5 mg/kg/day was given subcutaneously or intravenously beginning on the fifth day after stem cell reinfusion until the ANC was 41000/mm 3 .
Toxicity and response evaluations
Toxicity was graded using the National Cancer Institute Common Toxicity version II for Bone Marrow Transplant patients. Neutrophil engraftment was defined as the first day of 3 days of ANC 4 500, and platelet engraftment was defined as a count of 20000 or above without transfusion for 3 days. Molecular response was defined as documentation of absence of bcl-2 IgH gene rearrangement on PCR of blood or bone marrow following therapy if evidence of gene rearrangement seen on initial PCR of blood or bone marrow. Clinical responses were defined by the international working group criteria convened by the National Cancer Institute. 21 
Preparation of B Cell-HDM and purging
The Eligix B cell SC system consists of two types of separately vialed monoclonal antibody (mAb) -coated high-density microparticles (HDM), the CD19-HDM and CD20-HDM, as well as accessory sterile disposables and devices for carrying out the treatment process. One vial of each of the HDM is combined to create the Eligix B cell SC product at the time of use. A set of six vials, three containing 10 ml of CD20-HDM and three containing 10 ml of CD19-HDM, were used for each PBSC sample, as previously described. 16 Using aseptic procedures in a class II type A, biosafety cabinet or laminar flow hood and following Universal Precautions, the contents of each vial of CD20-HDM and CD19-HDM were transferred to a 225 ml depletion chamber. The pellet in each depletion chamber was demagnetized using a degausser, before the stem cell sample was added to the chamber.
After removing samples for testing, the PBSC were added to the first depletion chamber containing the Eligix B cell SC reagents. The depletion chamber was agitated to suspend the particles and placed on the cell processor, for mixing in a slow end-over-end motion for a time period of 10 min. The depletion chamber was then left upright on the cell processor for 5 min, and the magnet base was secured to the bottom of the depletion chamber while the CD19+/ CD20+-cell depleted cell suspension was transferred into a second depletion chamber containing SC reagents. This process was repeated for a total of three rounds of depletion. The PBSC product was then transferred to a final processing chamber, secured to the magnet base, and placed on the cell processor for 10 min, then washed twice. Samples for cell counts, CD34+cell enumeration, immunophenotyping, and PCR were removed and cryopreserved for future analysis. The Eligix B cell SC-processed product was then cryopreserved and thawed immediately before infusion.
Immunocytochemistry evaluation
An immunocytochemical assay for detection of rare events was modified and developed to detect total CD20+ B cells in the PBSC products pre-and post-processing. 22 Briefly, mononuclear cells were isolated by Ficoll-Hypaque separation (Pharmacia, Upsala, Sweden), washed twice in Leibovitz L-15 medium (GIBCO/BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum and resuspended to a concentration of 1 Â 10 7 cells/ml. 3 Â 10 6 cells were placed on slide cytopreparations and immunostained. Cytopreparations were fixed with paraformaldehyde/methanol, washed thoroughly in D-PBS and incubated with murine monoclonal antibody, anti-human CD20 (Coulter, FL, USA). Alkaline phospatase (AP) immunostaining was performed as previously described. Slides were evaluated by one reviewer and the total number of CD20+ cells per slide were recorded.
Quantitative PCR
Quantitative PCR was performed at the Blood Center of Southeastern Wisconsin after genomic DNA was isolated on the MagnaPure LC instrument (Roche Biochemical) using the DNA isolation I kit. DNA was quantified by absorbance at 260 nm. Nested 5 0 -primers for the major (mbr) and minor (mcr) breakpoint regions were derived from Gribben et al. 23 A primer sequence homologous to the consensus region J segments 1-6 was used as a 3 0 primer. 24 Seminested PCR was performed as previously described. 14 The sensitivity of the assay was determined using serial dilutions of DNA from cell lines containing mbr and mcr translocations (SUDHL6 and SUDHL16). Approximately 10000 positive cells within a population of one million normal cells are detectable after one round of PCR, and after two rounds of PCR it is possible to detect between 10 and 100 positive cells within a population of one million normal cells. This assay is capable of detecting approximately 70% of the reported translocations.
Statistics
DFS is defined as the time from the date of first infusion/ transplant to disease recurrence or death from any cause. Patients alive without a recurrence are censored at the date of last contact. DFS was estimated by the method of Kaplan and Meier. 25 Association between categorical variables was assessed by Fisher's exact test. The associations of CD20 count pre-purge, and time of previous rituximab, or outcome post-transplant was assessed by the exact Wilcoxon Test. An alpha less than or equal to 0.05 was considered as significant.
Results

Patients
In all, 29 patients were enrolled. Eight patients either did not reach the target of 15 CD34+ cells/ml or failed to mobilize adequate numbers of stem cells, and were removed from the study. Of the 21 patients (11 females) who were treated, 15 patients had follicular lymphoma grade I/II, two patients had follicular lymphoma grade III, and four patients had transformed follicular lymphoma. Median age was 53 years. Six patients had B symptoms, and 11 patients had a history of bone marrow involvement with lymphoma. Five patients had received prior external beam radiation therapy to sites of bulk disease, and 12 patients had received prior rituximab therapy. Cytogenetics of bone marrow were performed in 14 patients, and only one patient had a detectable clonal abnormality [t(1;10) ]. This information is detailed in Table 1 .
B cell depletion and purging results
Adequate immunohistochemistry samples were available on 16 patients. Using immunocytochemistry on apheresis products, the median number of CD20+ cells pre-purge was 310/10 6 (range 0-16692) and post-purge was 0.75/10 6 (range 0-7). One patient had both pre-CD20 and post-CD20 equal to 0. Excluding this patient, the median log depletion from pre-purge to post purge for the remaining 16 patients was 2.7 (range from 1.4 to 3.9); nine of these patients had CD20 o1 post purge. There was no relationship between CD20 count pre-purge, and time of previous rituximab (P ¼ 0.5) or outcome post-transplant (P ¼ 0.35). However, there was a trend toward an inverse association between log depletion and subsequent relapse after ASCT (P ¼ 0.06). Semi-nested PCR amplification at the major breakpoint region and minor cluster region of the bcl-2/IgH rearrangement of t(14;18) was then performed in stem cell products pre and post ex vivo purging. Of 17 patients with adequate samples, only four patients had a detectable breakpoint pre-purge; after purging, one had a 2-3 log depletion of malignant cells, one had a 1-2 log depletion and two had only 10-100 copies detected both pre-and post purge. Three of these four patients have had disease progression post ASCT. In all, 13 patients had negative PCR evaluation pre-purging; five of these patients have had disease progression post ASCT. There is no association between PCR status and clinical outcome after ASCT (two-sided Fisher's exact test, P ¼ 0.29). This information is summarized in Table 2 .
Engraftment, toxicity, and clinical outcome
Post-purging, a median of 4.3 Â 10 6 CD34+ cells/kg (range 2.46-19.45 Â 10 6 /kg) were infused. All patients completed high-dose chemotherapy and there was no significant infusional toxicity associated with the B-cell-depleted autologous stem cell products. One patient experienced grade 3 pulmonary toxicity, one patient experienced grade 3 neurological toxicity, and there were two severe infections; all resolved after engraftment. Two patients developed delayed pulmonary toxicity requiring prolonged corticosteroid therapy. There were no transplant-associated deaths. By day 14 after stem cell infusion, all 21 patients had ANC 4500/mm 3 . In all, 12 patients (57%) had platelet engraftment by day 14, and the remaining patients had platelet engraftment on days 16, 18, 19, 20, 23 and 37, respectively. The median number of days to platelet engraftment was 13 days (range 7-37). (Table 3) At a median follow-up of 18 months, 11 patients remain alive and free of lymphoma (Figure 1) , and the DFS at 18 months is 62%. In all, 10 patients have had progressive disease, and one patient has died from progressive NHL.
Discussion
The present study supports the previously published experience, 16 that the Eligix B Cell SC system efficiently removes B cells from PBSC products, does not increase infusional toxicity, and does not delay time to engraftment. This device does not have the inherent limitations of monoclonal antibody and complement processing, including the inability to standardize the biologic activity of complement as well as the long processing times and large quantities of biologic materials required for ex vivo treatment of large numbers of cells. This device also appears to have advantages over 'positive' CD34+ selection, an alternative purging modality for ASCT previously evaluated in follicular NHL and myeloma. 26, 27 Studies of CD34+ cell selection have demonstrated poor lymphocyte recovery post ASCT, suggesting an impact on nontargeted T cells, and subsequent prolonged immunodeficiencies. 28 There were no opportunistic infections in the present series, and engraftment post ASCT was not delayed.
A surprising finding in our study was the low rate of PCR-detectable disease in PBSC products of these patients, making it impossible to assess the efficiency of the Eligix B Cell SC system at eradicating minimal residual disease using PCR. Our prior experience evaluating bone marrow prior to ASCT would have predicted a higher rate of PCR-detectable disease, despite morphologic normalization of the marrow space. 23 Even though peripheral blood is generally less informative than bone marrow by PCR for t(14;18), 7 almost 50% of patients with follicular NHL in our prior series of bone marrow transplants had detectable disease in the blood that correlated with subsequent outcome after ASCT. 29 It is important to note that our previous experience was not with chemotherapy-mobilized peripheral blood, which may have an intrinsically lower rate of detectable disease. One additional explanation for the present finding is that 12 patients had received prior rituximab therapy three or more months prior to ASCT, which appears to clear peripheral blood of PCR detectable disease preferentially, 6 and has a prolonged half-life. 30 The relatively low numbers of B cells in the PBSC collections in this cohort support this conclusion.
Despite the high rate of PCR-negative stem cell products, the progression-free survival in the present study is possibly inferior to what would be predicted with purged bone marrow transplantation of PCR-negative products. 14 The present study did have less stringent selection criteria than our prior series, allowing patients with larger lymph node masses and a greater percentage of marrow involvement. The current study utilized chemotherapy-only conditioning rather than total body irradiation; however, several studies in patients with lymphoma indicate equivalent outcome with chemotherapy-only regimens. 31, 32 The difference in outcome may also be a result of in vivo mAb therapy with rituximab affecting the fidelity of molecular remission as a marker for freedom from disease progression. In a series of patients with mantle cell lymphoma treated with standard-dose CHOP and rituximab, patients who achieved molecular remissions in peripheral blood or bone marrow did not have improved progression-free survival compared to patients without molecular remissions. 33 Similar findings suggesting that PCR is not predictive of outcome in the setting of biologic therapy have been observed in a group of patients with follicular lymphoma treated with standard chemotherapy and interferon. 8 This observation has important implications in interpreting molecular response following ASCT. Preliminary results of trials utilizing rituximab as in vivo purging prior to ASCT have suggested high molecular response rates. [34] [35] [36] [37] Long-term follow-up of these studies is required to establish PCR as a reliable surrogate marker of clinical response in this situation.
The role of purging in ASCT for follicular NHL remains controversial. 38 It is presently unknown whether the infusion of residual lymphoma cells remaining after purging contributes directly to relapse, or whether the inability of purging to eradicate lymphoma cells is a marker of disease less sensitive to high-dose therapy. Indirect evidence that residual tumor cells contribute to relapse has been shown in aggressive lymphomas, where the ability to culture NHL cells from the harvested stem cell product is highly predictive of subsequent relapse following high-dose therapy. 39 Only randomized studies will be able to establish the true benefit of a particular purging technique. These studies are difficult to execute, and a European trial randomizing responding patients with follicular lymphoma to conventional chemotherapy, unpurged ASCT, or magnetic ex vivo purged ASCT, closed prematurely due to slow accrual, and therefore was not powered to definitively establish benefit to purging. 40 In our study, extent of B cell depletion was inversely proportional to relapse rate, suggesting that patients with a high number of B cells in PBSC products may benefit from purging interventions. This group should be targeted in future evaluations of both in vivo and ex vivo purging modalities. Finally, in the setting of ASCT following in vivo mAb therapy, clinical endpoints must remain the standard to evaluate outcome in patients with follicular NHL.
